RxDoctor Payments Data

Angel Malavet, MD

Internal Medicine · Corning, NYNPI 1225009095

Payments from drug & device makers

$1,351in general payments, 2019–2025

Across 59 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$908
  • AstraZeneca$195
  • Novo Nordisk$153
  • Pfizer$29
  • Merck$27
  • Exact Sciences$27
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)40$908
AstraZeneca5$195
Novo Nordisk8$153
Pfizer2$29
Merck2$27
Exact Sciences1$27
Johnson & Johnson1$12

How this compares

$1,351 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$135,801
Medicare patients
461
Services billed
2,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide138$168,570
EliquisApixaban178$166,846
OzempicSemaglutide134$146,103
JardianceEmpagliflozin119$115,907
JanuviaSitagliptin Phosphate65$79,235
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog87$67,202
XareltoRivaroxaban75$66,632
FarxigaDapagliflozin Propanediol64$50,562
CreonLipase/Protease/Amylase12$38,835
VraylarCariprazine Hcl21$31,455
Lantus SolostarInsulin Glargine,hum.Rec.Anlog142$23,054
Humulin R U-500Insulin Regular, Human16$22,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,381
TradjentaLinagliptin23$18,800
Tresiba Flextouch U-100Insulin Degludec20$18,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$166,846178 claims
Novo NordiskOzempic$153$146,103134 claims
MerckJanuvia$27$79,23565 claims
AbbVieCreon, Vraylar$908$70,29133 claims
Johnson & JohnsonXarelto$12$66,63275 claims
AstraZenecaFarxiga, Symbicort$195$58,25284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Corning

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →